TRIUMPH-4 Phase 3: 28.7% Weight Loss — The Strongest Obesity Drug Data Ever Recorded
Eli Lilly announced topline results from TRIUMPH-4, the first Phase 3 TRIUMPH trial to report. At the 12mg dose over 68 weeks, retatrutide produced an average of 28.7% body weight reduction — surpassing its own Phase 2 results and setting a new benchmark for non-surgical weight loss. Patients also experienced up to 75.8% reduction in knee osteoarthritis pain scores. A new safety signal — dysesthesia (abnormal skin sensations) — emerged in 20.9% of 12mg patients and is being monitored in seven upcoming 2026 readouts.
Read Lilly's official press release →Recent Coverage
Retatrutide Named a Drug of the Decade — $30 Billion in Sales Projected by 2031
Clarivate's Drugs to Watch 2026 report named retatrutide among the top 11 pipeline drugs of the next decade. Analysts project $30 billion in annual revenue by 2031 — $10B in obesity and $20B in diabetes indications. Commercial launch is projected for 2028.
Read at Pharmaceutical Executive →FDA Filing Possible in 2026 — Lilly Completing Seven Final TRIUMPH Trials
NBC News reports a Lilly spokesperson confirmed the company could file for FDA approval as early as 2026. Seven additional TRIUMPH trials are on track to complete this year. The piece situates retatrutide in the broader weight loss drug race alongside orforglipron and CagriSema.
Read at NBC News →Retatrutide Scores "Triple Trial Triumph" — But Dysesthesia Safety Signal Emerges at 12mg
BMO Capital Markets called TRIUMPH-4 results "a true TRIUMPH." The piece examines the new dysesthesia signal — affecting 20.9% of 12mg patients — and notes analysts are watching TRIUMPH-1 closely, which may exceed 30% weight loss due to its 80-week duration.
Read at BioSpace →TRIUMPH-4 Deep Dive: Nearly Half of Patients Achieved 25%+ Weight Loss
Detailed analysis of TRIUMPH-4 data showing nearly half of retatrutide patients achieved at least 25% weight loss, and approximately 1 in 8 reported being completely free of knee pain at week 68. GlobalData projects a 2027 approval and $15.6 billion in 2031 sales.
Read at Clinical Trials Arena →"Triple G" Drug Shows Promise — Seven More Phase 3 Readouts Due in 2026
ABC News covers retatrutide for a mainstream audience following the TRIUMPH-4 announcement. The piece explains the triple receptor mechanism and confirms Eli Lilly plans to submit Phase 3 data to the FDA, with approval considered unlikely before late 2026 at the earliest.
Read at ABC News →Live News Feed
Loading latest retatrutide news...